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Perhaps it is better to be irresponsible and right than to be
responsible and wrong.
‘Only constant repetition will finally succeed in imprinting an
idea on the memory of the crowd.
When I took my A-level examinations in 1966, I was taught that in
order to excel in the essay-writing section, one should always
begin with a quotation and ascribe it to Winston S Churchill.
‘After all’, my teacher would say, ‘Churchill said and wrote so
much that no one will ever know the difference!’ Well, 33 years
later, my style has not changed … yet at least the first quotation
is genuine Churchill … Party Political Broadcast, London, 26
August 1950. Moreover, we are certainly dealing with a heated
issue of responsibility/irresponsibility and right/wrong. Every
physician, scientist and patient desires the same goal – to obtain
initial clinical experience of a new therapy with a minimum
amount of animal toxicology, at a sufficiently safe starting dose
and requiring the minimal number of dose calations to establish
the appropriate dose.
Choosing the extreme conservative side of this paradigm neces-
sitates the sacrifice of hundreds of thousands of animals unneces-
sarily and subject large numbers of patients to being treated at
doses which are sub-therapeutic (Collins et al, 1986; Collins et al,
1990; Penta et al, 1992; Ratain et al, 1993; Simon et al, 1997).
Choosing the most aggressive approach, we save animals,
money and time in the developmental process, but have the poten-
tial of killing patients by introducing drugs at unsafe doses.
The vast majority of pharmaceutical/biotechnology companies
at the present time introduce their cancer drugs after full toxicity
evaluation in both rodent and non-rodent species. By doing so, few
would argue that they are ‘right’ in terms of conservatism with the
patients’ starting dose, and certainly ‘right’ in presenting regula-
tory bodies with more than enough information to satisfy the
rigors of taking the drug into the clinic. The burning issue, of
course, is whether they would still be ‘responsible’ in introducing
a drug into the clinic with significantly less toxicology.
In the same year that I took my A-level examinations, EJ
Freireich published a seminal paper on the quantitative compar-
ison of toxicity of anticancer agents in mouse, rat, hamster, dog,
monkey and man in Cancer Chemotherapy Reports (Freireich
et al, 1966). They noted ‘these results support the conclusion that
the experimental test systems (the relationship of LD10 in animals
to MTD in man) used to evaluate the toxicities of potential anti-
cancer drugs correlate remarkably closely with the results in man.’
Since that time (33 years ago!), the literature is replete with
studies, reviews and editorials in an attempt to define the minimal
data set required to predict a safe LD10/MTD (maximum tolerated
dose) projection (Freireich et al, 1966; Homan, 1972; Goldsmith
et al, 1975; Penta et al, 1979; Rozencweig et al, 1981; Grieshaber
and Marsoni, 1986; Penta et al, 1992; Arbuck et al, 1996; Dent
and Eisenhauer, 1996). The paper by Newell et al in this issue
(see pp. xxx) is not only the latest paper in this field, but also one of
the most comprehensive in its database, review and discussion. It
contains derived data from a compilation of numerous preclinical
and clinical studies. Indeed, prior to its publication, the vast
majority of people in the field knew that the Cancer Research
Campaign (CRC) experience with preclinical toxicology appeared
to provide a safe starting dose of phase I clinical trials of cytotoxic
anticancer agents.
This manuscript ventures somewhat further in its attempt to
equate qualitative toxicity between mice and humans. This is diffi-
cult since only acute effects to a few tissues are examined in
animal studies while human trials include a more comprehensive
evaluation. Nevertheless, the qualitative associations are present
for certain classes of new drugs. This area of the manuscript might
benefit from the addition or the inclusion of National Cancer
Institute (NCI) or industry experiences with ‘non-rodent’ studies
to be able to state whether they would or would not add pertinent
information, particularly on qualitative toxicities. This would
enable the question of ‘compared to non-rodent’ to be addressed
rather than simply stating the non-rodent species is/was not
required. However, speaking personally (and, in an editorial, one
is permitted to express personal opinions), I care somewhat less
about the qualitative toxicity relationship. The critical issue to all
of us must surely be the minimal data set of animal toxicology
required to safely introduce the drug at an appropriately ‘high’
level in patients.
The discussion of the Newell manuscript refers to the critical
examples where initiation of phase I trials at one-tenth of the
mouse MTD/LD10 would have exceeded the human MTD.
Without repeating the body of the text, the authors point out
appropriately that compounds subject to intracellular metabolic
activation may well require species-specific or other careful
testing in selecting the suitable phase I trials starting dose.
However, the authors conclude that for routine testing, one-tenth
of the mouse MTD/LD10 represents a safe phase I trial starting
dose.
It is an obligation for the writer of any editorial to be objective
and as such, I have sought hard to fault the conclusions of this
seminal paper. However, as I have consulted my toxicology
friends and colleagues, I am assured that opinions on full non-
rodent toxicology have significantly changed over the past 20
years; moreover, I am reassured that our regulatory colleagues are
taking the data in this manuscript extremely seriously. It must be
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present time requires a second, non-rodent species in order to test
the safety of the estimated starting dose only for clinical studies
and not full dose-escalating non-rodent toxicology. Moreover, the
second non-rodent species can, to the best of my understanding, be
a rabbit or another appropriate experimental species rather than a
dog (DeGeorge et al, 1998). Of course, such an approach would
need a full discussion with the FDA beforehand. However, the vast
majority of drugs entering the clinic significantly exceed the
FDA’s absolute requirements.
And so to the second quotation on ‘repetition’ (a bottle of malt
scotch to the first colleague who correctly e-mails me with the
author) and to the reflection upon the remarkable life of Brian Fox
who passed away on 28 March 1999; I find it the most humbling
honour to write the editorial for his last manuscript. Chuck
Grieshaber, who helped me write this editorial, first had the privi-
lege to meet Brian Fox almost 20 years ago during the initial
debates over the design and expectation of preclinical toxicology
studies for new anticancer agents. At the time, Dr Fox and Dr Tom
Connors were playing major roles in the establishment of the CRC
Phase I/II Committee with the purpose of advancing new anti-
tumour agents to clinical study as rapidly as possible. For a few
years prior, Drs Fox and Connors were proposing a process where
drugs would transit the laboratory–clinic bridge as a two-way
street. The basic tenet held that the ultimate test of the value of a
new modality rests in human studies. Non-clinical and experi-
mental studies should support the trial not paralyse it! Amen. This
is a simple paradigm that went largely unnoticed, or at least
unheeded, in the USA until translational research became the
byword for contemporary drug development over the past half
decade involving the new molecular technologies and target-
oriented clinical trials. Brian was continually stating the case for
‘minimal’ toxicology studies. By this he meant essentially the
studies reported in the manuscript.
The themes of minimal toxicology studies and advancing new
agents to clinical studies as rapidly as possible were brought
to international impact by Brian’s Vice-Chairmanship and
Chairmanship of the Screening and Pharmacology Group of
EORTC between 1979 and 1988 and by Brian’s membership of the
NCI-EORTC Joint Steering Committee between 1980 and 1993.
Regrettably, although preclinical and clinical development times
have overall decreased, ‘constant repetition’ with regard to
minimal toxicology studies has not yet succeeded in ‘imprinting
the idea on the memory of the crowd’. I believe that the time has
come for everyone involved in anticancer drug development to re-
evaluate their current practice of animal toxicology. As a first step,
we need to ask ourselves why toxicology testing on new cytotoxic
or cytostatic agents in the USA so often significantly exceeds the
current FDA requirements. Could not the PhRMA or some other
pharmaceutical industry organization meet with the regulatory
authorities to define a minimal agreed toxicology set for cytotoxic
drugs? Secondly, in terms of the UK (and some other European
countries), the unusual thing is not that the regulations are different
but rather that ‘exemptions’ to some of the guidelines may apply if
the trial is sponsored by a physician rather than a company. The
DDX in the UK is one example. Should now the exemption not
become the rule? Thirdly, the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH), established in 1990, is a
unique project that brings together the regulatory authorities of
Europe, Japan and the US and experts from the pharmaceutical
industry in the three regions to discuss scientific and technical
aspects of product registration. ‘The objective of such harmonisa-
tion is a more economical use of human, animal and material
resources, and the elimination of unnecessary delay in the global
development and availability of new medicines whilst maintain-
ing safeguards on quality, safety and efficacy, and regulatory
obligations to protect public health’ (ICH website: http://
www.ifpma.org/ich1.html). It is imperative that their Steering
Committee meet at the earliest possible convenience to discuss the
significance of this publication. Two final points:
1. Clinicians are now saving time in the drug development
process by other strategies such as enrolling only one patient
per level and adopting more aggressive, often pharmacokineti-
cally guided, dose escalation schemes. This often happens to
compensate for a conservatively low starting dose. However,
Chuck and I actually believe that the phase I assessment
methods now considered are directly the result of phase I
physicians not receiving the predictions required for
sufficiently high starting doses and safe escalation procedures
from the current toxicology data. Hence, what are we truly
gaining from the time delay, not to mention the number of
dogs sacrificed, in the non-rodent animal testing?
2. Now, more than ever, in the light of the hormonal, biological,
immunological and targeted moieties, in which biologically
active dose is often unrelated to maximally tolerated dose,
entirely new models of animal testing are mandated. There is
no question that much laboratory work is essential to under-
stand the pharmacology of these new modalities; however,
toxicology studies designed to define safety should never be
limiting in the translation of drugs to clinical trial. We know
that this is what Brian would have wished for as a significant
slice of his professional legacy.
Brian did not have one distinguished career … but at least three.
Beyond his oncology expertise, he was a Past-President and active
member of the British Lichen Society and a member of the presti-
gious Linnaen Society. His books, papers and reports will form ‘a
substantial contribution to the annals of natural history to be
consulted by many who follow in his footsteps (Dr AT McGown,
Christie CRC Research Centre, Paterson Institute for Cancer
Research, University of Manchester, UK). Thirdly, Brian was an
avid historian of the Christie Hospital and made a unique collec-
tion of the research papers of distinguished scientists and physi-
cians together with detail of the medical advances associated with
oncology in this area of the world. In a paper he published in 1998
on the history of radium in medicine in Manchester (Fox, 1998),
he spoke of the introduction of new remedies to treat cancer in the
early part of this century. He noted that ‘like a modern ethics
committee, the hospital doctors tried to strike a balance between
the aspirations of a novel treatment, while, at the same time,
protecting the interest of the patient’. The best eulogy that we, as a
cancer community, could offer to Brian is to strike the appropriate
balance between minimal toxicology testing for cytotoxic agents
while safely advancing these into current pharmaceutical practice.
Moreover, in bringing the newer ‘non-cytotoxic’ treatment modal-
ities into oncology practice, let us not repeat the errors of the past
but instead design innovative preclinical testing requiring a
minimum of toxicology in order to advance these new modalities
into the clinic as rapidly as possible.
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